Literature DB >> 28772101

Propagation of Tau Aggregates and Neurodegeneration.

Michel Goedert1, David S Eisenberg2, R Anthony Crowther1.   

Abstract

A pathway from the natively unfolded microtubule-associated protein Tau to a highly structured amyloid fibril underlies human Tauopathies. This ordered assembly causes disease and represents the gain of toxic function. In recent years, evidence has accumulated to suggest that Tau inclusions form first in a small number of brain cells, from where they propagate to other regions, resulting in neurodegeneration and disease. Propagation of pathology is often called prion-like, which refers to the capacity of an assembled protein to induce the same abnormal conformation in a protein of the same kind, initiating a self-amplifying cascade. In addition, prion-like encompasses the release of protein aggregates from brain cells and their uptake by neighboring cells. In mice, the intracerebral injection of Tau inclusions induces the ordered assembly of monomeric Tau, followed by its spreading to distant brain regions. Conformational differences between Tau aggregates from transgenic mouse brain and in vitro assembled recombinant protein account for the greater seeding potency of brain aggregates. Short fibrils constitute the major species of seed-competent Tau in the brains of transgenic mice. The existence of multiple human Tauopathies with distinct fibril morphologies has led to the suggestion that different molecular conformers (or strains) of aggregated Tau exist.

Entities:  

Keywords:  Alzheimer's disease; Pick's disease; Tau; Tauopathies; amyloid; cell-to-cell spreading; disease propagation; prion-like; protein strains; toxicity

Mesh:

Substances:

Year:  2017        PMID: 28772101     DOI: 10.1146/annurev-neuro-072116-031153

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  166 in total

1.  Tau Interacts with the C-Terminal Region of α-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations.

Authors:  Anvesh K R Dasari; Rakez Kayed; Sungsool Wi; Kwang Hun Lim
Journal:  Biochemistry       Date:  2019-06-07       Impact factor: 3.162

2.  4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

Authors:  Eri Saijo; Michael A Metrick; Shunsuke Koga; Piero Parchi; Irene Litvan; Salvatore Spina; Adam Boxer; Julio C Rojas; Douglas Galasko; Allison Kraus; Marcello Rossi; Kathy Newell; Gianluigi Zanusso; Lea T Grinberg; William W Seeley; Bernardino Ghetti; Dennis W Dickson; Byron Caughey
Journal:  Acta Neuropathol       Date:  2019-10-16       Impact factor: 17.088

3.  Structure-based inhibitors of amyloid beta core suggest a common interface with tau.

Authors:  Sarah L Griner; Paul Seidler; Jeannette Bowler; Kevin A Murray; Tianxiao Peter Yang; Shruti Sahay; Michael R Sawaya; Duilio Cascio; Jose A Rodriguez; Stephan Philipp; Justyna Sosna; Charles G Glabe; Tamir Gonen; David S Eisenberg
Journal:  Elife       Date:  2019-10-15       Impact factor: 8.140

4.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

Authors:  Lorena Saelices; Kevin Chung; Ji H Lee; Whitaker Cohn; Julian P Whitelegge; Merrill D Benson; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

Review 5.  Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.

Authors:  Fred Yeboah; Tae-Eun Kim; Anke Bill; Ulf Dettmer
Journal:  Neurobiol Dis       Date:  2019-07-24       Impact factor: 5.996

6.  In vitro 0N4R tau fibrils contain a monomorphic β-sheet core enclosed by dynamically heterogeneous fuzzy coat segments.

Authors:  Aurelio J Dregni; Venkata S Mandala; Haifan Wu; Matthew R Elkins; Harrison K Wang; Ivan Hung; William F DeGrado; Mei Hong
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-29       Impact factor: 11.205

7.  Regulatory mechanisms of tau protein fibrillation under the conditions of liquid-liquid phase separation.

Authors:  Solomiia Boyko; Krystyna Surewicz; Witold K Surewicz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

8.  TauBI or not TauBI: what was the question?

Authors:  Magdalena Sastre; Fred Van Leuven; Steve M Gentleman
Journal:  Brain       Date:  2018-09-01       Impact factor: 13.501

9.  Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.

Authors:  Romany Abskharon; Paul M Seidler; Michael R Sawaya; Duilio Cascio; Tianxiao P Yang; Stephan Philipp; Christopher Kazu Williams; Kathy L Newell; Bernardino Ghetti; Michael A DeTure; Dennis W Dickson; Harry V Vinters; Philip L Felgner; Rie Nakajima; Charles G Glabe; David S Eisenberg
Journal:  J Biol Chem       Date:  2020-06-03       Impact factor: 5.157

Review 10.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.